Walleye Capital LLC Takes Position in Annexon, Inc. (NASDAQ:ANNX)

Walleye Capital LLC bought a new stake in Annexon, Inc. (NASDAQ:ANNX) during the third quarter, HoldingsChannel reports. The firm bought 328,698 shares of the company’s stock, valued at approximately $1,946,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in Annexon by 96.4% in the 1st quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock worth $26,871,000 after purchasing an additional 1,839,329 shares during the last quarter. Comerica Bank acquired a new stake in Annexon during the first quarter valued at approximately $72,000. DNB Asset Management AS lifted its stake in Annexon by 29.4% during the second quarter. DNB Asset Management AS now owns 46,485 shares of the company’s stock valued at $228,000 after purchasing an additional 10,574 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Annexon during the second quarter valued at approximately $944,000. Finally, Bank of New York Mellon Corp lifted its stake in Annexon by 42.9% during the second quarter. Bank of New York Mellon Corp now owns 258,033 shares of the company’s stock valued at $1,264,000 after purchasing an additional 77,417 shares during the last quarter.

Insider Transactions at Annexon

In other news, EVP Ted Yednock sold 5,408 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total transaction of $40,073.28. Following the transaction, the executive vice president now owns 71,365 shares in the company, valued at approximately $528,814.65. The trade was a 7.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 12.67% of the company’s stock.

Annexon Price Performance

Shares of ANNX opened at $5.16 on Thursday. The company’s fifty day moving average price is $6.54 and its 200 day moving average price is $5.97. Annexon, Inc. has a one year low of $2.27 and a one year high of $8.40. The company has a market capitalization of $550.00 million, a PE ratio of -4.91 and a beta of 1.10.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ANNX shares. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Annexon in a research report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $15.80.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.